Pfizer's Leslie Koby and Dr. Seemal Desai on Advancing Health Equity in Medical Dermatology

The video discusses the significance of HealthEquity in dermatology, highlighting the need for diverse representation in clinical trials and the challenges in diagnosing skin conditions across different skin tones. It emphasizes the importance of education and collaboration between industry and healthcare professionals to improve patient care and access to therapies.

Why is Health Equity particularly important in the field of dermatology?

• Because skin diseases affect everyone equally.

• Because dermatology relies on visual examination and decision-making.

• Because all skin types are the same.

• Because it is not relevant to dermatology.

What is a significant challenge in diagnosing atopic dermatitis in diverse populations?

• There are no challenges in diagnosing it.

• Symptoms like redness can be masked in darker skin tones.

• Symptoms are easily visible in all skin tones.

• The disease does not affect diverse populations.

What percentage of African Americans are part of Pfizer's clinical trials?

• 10%

• 50%

• 38%

• 25%

What is one of the key actions the industry can take to improve Health Equity?

• Stop conducting clinical trials.

• Ignore diverse patient populations.

• Focus only on white skin in clinical trials.

• Invest in education and research for diverse populations.

Why is it important to have diverse representation in clinical trials?

• To focus only on one racial group.

• To make trials shorter.

• To reduce the number of participants.

• To ensure outcomes data is representative of all populations.